Paper8985191
A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.
Boursnell ME and 11 others. J Infect Dis, 1997. Cited by 140 papers, by iCite.
Cite this record
ConductScience Library. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. Papers, record 8985191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8985191
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Herpes Genitalis | Major topic |
| Herpesvirus 2, Human | Major topic |
| Vaccines, Synthetic | Major topic |
| Viral Vaccines | Major topic |
| Animals | |
| Antibodies, Viral | |
| Chlorocebus aethiops | |
| Female | |
| Gene Deletion | |
| Genes, Viral | |
| Guinea Pigs | |
| Immunization Schedule | |
| Recurrence | |
| Transfection | |
| Vaccination | |
| Vaccines, Inactivated | |
| Vero Cells | |
| Viral Envelope Proteins | |
| Virus Replication |
Source PubMed
Cited by53
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40127471 | Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy. | Hum Vaccin Immunother | 2025 | https://conductscience.org/library/papers/40127471 | PubMed |
| 39982077 | Tackling cutaneous herpes simplex virus disease with topical immunomodulators-a call to action. | Clin Microbiol Rev | 2025 | https://conductscience.org/library/papers/39982077 | PubMed |
| 39508503 | An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application. | Virulence | 2024 | https://conductscience.org/library/papers/39508503 | PubMed |
| 39226323 | A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion. | PLoS Pathog | 2024 | https://conductscience.org/library/papers/39226323 | PubMed |
| 36851084 | An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections. | Vaccines (Basel) | 2023 | https://conductscience.org/library/papers/36851084 | PubMed |
| 36312660 | Effective Treatment of Diabetes Mellitus by Resonance Medicine. | Cureus | 2022 | https://conductscience.org/library/papers/36312660 | PubMed |
| 35547736 | Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. | Front Immunol | 2022 | https://conductscience.org/library/papers/35547736 | PubMed |
| 32963118 | Alphaherpesvirus Vaccines. | Curr Issues Mol Biol | 2021 | https://conductscience.org/library/papers/32963118 | PubMed |
| 29899091 | Immunization by Replication-Competent Controlled Herpesvirus Vectors. | J Virol | 2018 | https://conductscience.org/library/papers/29899091 | PubMed |
| 29176979 | US6 Gene Deletion in Herpes Simplex Virus Type 2 Enhances Dendritic Cell Function and T Cell Activation. | Front Immunol | 2017 | https://conductscience.org/library/papers/29176979 | PubMed |
| 28848543 | A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells. | Front Immunol | 2017 | https://conductscience.org/library/papers/28848543 | PubMed |
| 28082979 | Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs. | Front Immunol | 2016 | https://conductscience.org/library/papers/28082979 | PubMed |
| 25756612 | Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. | Elife | 2015 | https://conductscience.org/library/papers/25756612 | PubMed |
| 25649429 | Systemic antibody response to nano-size calcium phospate biocompatible adjuvant adsorbed HEV-71 killed vaccine. | Clin Exp Vaccine Res | 2015 | https://conductscience.org/library/papers/25649429 | PubMed |
| 25077372 | Prospects and perspectives for development of a vaccine against herpes simplex virus infections. | Expert Rev Vaccines | 2014 | https://conductscience.org/library/papers/25077372 | PubMed |
| 23843891 | Towards an effective genital herpes vaccine: past lessons and future prospects. | Future Virol | 2007 | https://conductscience.org/library/papers/23843891 | PubMed |
| 23837576 | A single gD glycoprotein can mediate infection by Herpes simplex virus. | J Am Chem Soc | 2013 | https://conductscience.org/library/papers/23837576 | PubMed |
| 23365427 | Inhibition of the host translation shutoff response by herpes simplex virus 1 triggers nuclear envelope-derived autophagy. | J Virol | 2013 | https://conductscience.org/library/papers/23365427 | PubMed |
| 22318147 | Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. | J Virol | 2012 | https://conductscience.org/library/papers/22318147 | PubMed |
| 22146341 | Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells. | Mol Ther | 2012 | https://conductscience.org/library/papers/22146341 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GGH | 8836 | PubTator's text mining | https://conductscience.org/library/genes/8836 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8985191
GET https://conductscience.org/api/papers/v1/8985191/cited_by?page=2